Why Cryopreservation is No Longer Science Fiction | with Until Co-founder and CEO Laura Deming

What if we could pause biological time to wait for a cure for a disease? Thanks to innovations and research in reversible cryopreservation, this possibility is no longer just science fiction. Sarah Guo sits down with Laura Deming, CEO and co-founder of biotech startup Until, to dive deep into the growing field of reversible cryopreservation. Laura talks about how her time as a Thiel Fellow as well as her founding of the Longevity Fund fueled her obsession with solving the “social blindspot” of aging. Laura details how her new startup, Until, seeks to build tools that allow for “pressing pause” on biological time, starting with human organs with the hopes of scaling up to full body medical hibernation. Together, they also discuss why ice is the enemy of tissue, using engineering tools to help solve biological problems, and how this technology may revolutionize organ transplantation by removing time as a variable. Sign up for new podcasts every week. Email feedback to show@no-priors.com Follow us on Twitter: @NoPriorsPod | @Saranormous | @EladGil | @LauraDeming | @untillabs Chapters: 00:00 – Cold Open 01:08 – Laura Deming Introduction 01:53 – Why Laura Focused on Cryo Preservation and Longevity 06:20 – Bringing on Co-Founder Hunter Davis 07:55 – Until’s Goal 10:10 – Other Use Cases for Cryo Technology 12:22 – Scientific Challenges in Cryo Tech 15:36 – Using Engineering Principles to Solve Biological Problems 20:18 – Scaling Up Cryo Preservation 21:48 – Leading and Recruiting at Until 25:02 – Why Hasn’t Cryo Tech Been Worked On More? 27:14 – Making Time Not a Variable in Organ Transplants 29:06 – Changing How the Molecular World is Depicted 30:47 – Conclusion

Laura DemingguestSarah Guohost

Jan 29, 202630mWatch on YouTube ↗

EPISODE INFO

Released: January 29, 2026
Duration: 30m
Channel: No Priors
Watch on YouTube: ▶ Open ↗

EPISODE DESCRIPTION

What if we could pause biological time to wait for a cure for a disease? Thanks to innovations and research in reversible cryopreservation, this possibility is no longer just science fiction. Sarah Guo sits down with Laura Deming, CEO and co-founder of biotech startup Until, to dive deep into the growing field of reversible cryopreservation. Laura talks about how her time as a Thiel Fellow as well as her founding of the Longevity Fund fueled her obsession with solving the “social blindspot” of aging. Laura details how her new startup, Until, seeks to build tools that allow for “pressing pause” on biological time, starting with human organs with the hopes of scaling up to full body medical hibernation. Together, they also discuss why ice is the enemy of tissue, using engineering tools to help solve biological problems, and how this technology may revolutionize organ transplantation by removing time as a variable. Sign up for new podcasts every week. Email feedback to show@no-priors.com Follow us on Twitter: @NoPriorsPod | @Saranormous | @EladGil | @LauraDeming | @untillabs Chapters: 00:00 – Cold Open 01:08 – Laura Deming Introduction 01:53 – Why Laura Focused on Cryo Preservation and Longevity 06:20 – Bringing on Co-Founder Hunter Davis 07:55 – Until’s Goal 10:10 – Other Use Cases for Cryo Technology 12:22 – Scientific Challenges in Cryo Tech 15:36 – Using Engineering Principles to Solve Biological Problems 20:18 – Scaling Up Cryo Preservation 21:48 – Leading and Recruiting at Until 25:02 – Why Hasn’t Cryo Tech Been Worked On More? 27:14 – Making Time Not a Variable in Organ Transplants 29:06 – Changing How the Molecular World is Depicted 30:47 – Conclusion

SPEAKERS

Laura Deming
guest
Sarah Guo
host

EPISODE SUMMARY

In this episode of No Priors, featuring Laura Deming and Sarah Guo, Why Cryopreservation is No Longer Science Fiction | with Until Co-founder and CEO Laura Deming explores reversible cryopreservation roadmap: from transplant organs to human hibernation Until is developing reversible cryopreservation—cooling living systems enough to halt damage and “restart” them—by first targeting single-organ preservation for transplants.

RELATED EPISODES